This study compares two treatments for a specific type of lung cancer called non-small cell lung cancer (NSCLC) without certain genetic changes. One treatment, Datopotamab Deruxtecan (Dato-DXd), is being tested against an existing treatment, docetaxel. The study aims to find out which treatment works better and is safer. To be part of this study, patients must have NSCLC that is advanced or has spread to other parts of the body, test positive for a protein called TROP2, and have tried certain other treatments that didn't work.

• This study is open-label, meaning both doctors and patients know which treatment is being given.
• Participation involves random assignment to one of two treatment groups.
• Frequent monitoring and assessments will occur throughout the study.

It's important to know that this study is not suitable for patients who have certain other health issues, like severe lung problems or infections, or other cancers that have been active in the past 3 years.